[go: up one dir, main page]

WO2012089220A1 - Procédé de préparation d'une forme médicamenteuse soluble dans l'eau d'antibiotique issu du groupe des rifamycines et composition obtenue par ce procédé - Google Patents

Procédé de préparation d'une forme médicamenteuse soluble dans l'eau d'antibiotique issu du groupe des rifamycines et composition obtenue par ce procédé Download PDF

Info

Publication number
WO2012089220A1
WO2012089220A1 PCT/EA2011/000014 EA2011000014W WO2012089220A1 WO 2012089220 A1 WO2012089220 A1 WO 2012089220A1 EA 2011000014 W EA2011000014 W EA 2011000014W WO 2012089220 A1 WO2012089220 A1 WO 2012089220A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
antibiotic
rifamycins
pharmaceutical composition
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EA2011/000014
Other languages
English (en)
Russian (ru)
Inventor
Владимир Евстахиевич БАБИЙ
Алексей Владимирович ИГНАТЬЕВ
Светлана Эммануиловна ГЕЛЬПЕРИНА
Ольга Олеговна МАКСИМЕНКО
Людмила Витальевна ВАНЧУГОВА
Елена Владимировна ШИПУЛО
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "NAUCHNO-PROIZVODSTVENNYJ KOMPLEKS "NANOSISTEMA"
Original Assignee
OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "NAUCHNO-PROIZVODSTVENNYJ KOMPLEKS "NANOSISTEMA"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "NAUCHNO-PROIZVODSTVENNYJ KOMPLEKS "NANOSISTEMA" filed Critical OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU "NAUCHNO-PROIZVODSTVENNYJ KOMPLEKS "NANOSISTEMA"
Priority to AP2013007013A priority Critical patent/AP2013007013A0/xx
Priority to UAA201309032A priority patent/UA108527C2/uk
Publication of WO2012089220A1 publication Critical patent/WO2012089220A1/fr
Anticipated expiration legal-status Critical
Priority to ZA2013/05684A priority patent/ZA201305684B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Definitions

  • the present invention relates to the field of medicine, pharmacy, nanotechnology and colloid chemistry, in particular, to a method for producing a water-soluble dosage form (pharmaceutical composition) of an antibiotic from the group of rifamycins, such as rifabutin, rifampicin, rifapentin, rifaximin and their pharmaceutically acceptable derivatives for the treatment of tuberculosis .
  • rifamycins such as rifabutin, rifampicin, rifapentin, rifaximin and their pharmaceutically acceptable derivatives for the treatment of tuberculosis .
  • Rifamycins are a group of semisynthetic antibiotics formed by radiant fungi of the genus Streptomyces, as well as their semisynthetic derivatives.
  • One of the first antibiotics of this group, rifampicin ( Figure 1) which is a semi-synthetic derivative of rifamycin SV, has a wide spectrum of antibacterial activity and good solubility. Rifampicin is rapidly absorbed by intramuscular administration; maximum plasma concentration is reached after 30 minutes, the therapeutic concentration persists for 6-8 hours.
  • rifampicin Since rifampicin is soluble in water, its dosage form as an injection is known by dissolving 0.15 g of rifampicin in 2.5 ml of sterile water for injection, vigorously shaking the ampoule with the powder until complete dissolution and dilution of the resulting solution in 125 ml of 5% glucose solution; the specified solution is administered to the patient intravenously, at a rate of 60 to 80 drops per minute.
  • rifabutin whose chemical structure is 4-deoxo-3,4 - [2 -spiro [1H-isobutyl-4-piperaidyl] 2,5-dihydro-1 H-imidazole] (Fig. 2).
  • rifabutin is similar to rifampicin (the drug inhibits RNA synthesis by forming a complex with DNA-dependent RNA polymerase), however, it significantly exceeds its pharmacodynamic and pharmacokinetic properties.
  • the challenge remains to develop a soluble dosage form of rifabutin suitable for intravenous administration to a patient in need (when dissolved in an appropriate pharmaceutically acceptable carrier), while having a low toxicity and efficacy no less than traditional oral forms of this antibiotic.
  • the prior art method for producing a rifapentin dosage form suitable for intravenous administration to experimental animals comprising: dissolving rifapentin in 0.1 M NaHC0 3 containing 10% ⁇ , ⁇ -dimethylformamide and 0.001 M ascorbic acid, followed by adjusting the pH of the solution to 8.5-8.6 by adding 1 n. NaOH;
  • the rifapentin dosage form thus obtained was suitable for intravenous administration to experimental animals at a dose of 3 mg / kg body weight and 10 mg / kg body weight (Assandri A., Ratti B., Carlos T. Pharmacokinetics of rifapentine, a new long lasting rifamycin , in the rat, the mouse and the rabbit. - The Journal of Antibiotics, Sept. 1984, p. 1067).
  • the specified composition additionally contains a water-soluble natural or synthetic polymer stabilizer with a molecular weight of not more than 70 kDa and, if necessary, a lipid plasticizer and fillers at a certain quantitative ratio of the components.
  • the disadvantage of the nanosomal polylactide-based rifabutin dosage form is that the long-term intravenous dosage form can be toxic, and this toxicity is not due to rifabutin itself, but to the high concentration of the biodegradable polymer (PLGA or PLA) contained in the nanoparticles, which limits the possibility of further development and clinical use of such nanoparticles.
  • PLGA or PLA biodegradable polymer
  • the aforementioned analogue also discloses a pharmaceutical composition for treating tuberculosis and Helicobacter pylori-mediated diseases, which is a rifabutin solubilized albumin powder (lyophilizate) obtained by this method and having an average particle size of 4 to 10 nm, and when a pharmaceutically acceptable diluent or carrier is added - suitable for intravenous administration to a patient in need of this stable solution, characterized by an average particle size of from 4 to 10 nm.
  • the task to be solved by the claimed solution is aimed at simplifying the technology for producing a pharmaceutical composition of an antibiotic from a group of rifamycins, as well as eliminating highly toxic organochlorine solvents immiscible with water.
  • the claimed technical solution is aimed at obtaining a pharmaceutical composition of an antibiotic from the group of rifamycins suitable for parenteral (intravenous) administration to a patient in need thereof.
  • Said composition is obtained by a method comprising a) dissolving an antibiotic from the group of rifamycins in an organic solvent selected from the group of water-miscible solvents; b) adding to the solution obtained in stage a) an aqueous albumin solution obtained by dissolving 1-10% m / v albumin in sterilized demineralized water; c) mixing the resulting mixture; d) filtration; d) the addition of a cryoprotectant; e) freezing; g) drying (lyophilic or spray).
  • the mentioned method is carried out as follows: dissolve an antibiotic selected from the group of rifamycins in an organic solvent selected from the group of miscible with water solvents, for example, acetone, isopropanol, ethanol. Next, the resulting solution is added to an aqueous solution of human serum albumin and stirred, preferably on a mixer, until the organic solvent is completely removed, at a stirring speed of 300-400 rpm, or the organic solvent is removed by distillation under reduced pressure (using a rotary evaporator).
  • a cryoprotectant preferably selected from 1-5% mannitol, 1-5% glucose, 1-5% lactose or 1-5% trehalose, is added; they are frozen (at a temperature of -60-70 ° C) and lyophilized (or dried by spray drying). Lyophilisate powder when resuspending in the previous volume is characterized by an average particle size of 100-800 nm, and when diluted 100 times - 5-80 nm (determined by dynamic light scattering using the Malvern Zetasizer Nano ZS analyzer).
  • a pharmaceutical composition for treating tuberculosis and diseases caused by persistence in a Helicobacter pylori patient is an antibiotic powder (lyophilisate) from the rifamycin group solubilized with albumin, and when a pharmaceutically acceptable diluent and / or carrier is added, wherein the acceptable diluent or carrier is, for example, a 0.9% NaCI solution or additionally contains 0.1 -0.3% ascorbic acid, suitable for intravenous administration in need of this patient and is a stable suspension, while said lyophilisate and said suspension are characterized by ednim particle size of 200-800 nm, and upon dilution 100 times - 5- 80 nm, said lyophilizate prepared in accordance with the claimed invention method.
  • the acceptable diluent or carrier is, for example, a 0.9% NaCI solution or additionally contains 0.1 -0.3% ascorbic acid, suitable for intravenous administration in need of this patient and is a stable suspension, while said lyophilisate and said
  • rifabutin (Rb) 140 mg is dissolved in 1.7 ml of acetone and added to 100 ml of a 3% aqueous solution of human serum albumin. Stirred on a magnetic stirrer until the organic solvent is completely removed, at a stirring speed of 300-400 rpm, or the organic solvent is removed by distillation under reduced pressure (using a rotary evaporator); filtered through a glass filter (pore 1), cryoprotectant (3% trehalose) is added, frozen (at a temperature of -60-70 ° C) and lyophilized (or dried by spray drying).
  • the resulting lyophilizate powder when resuspended in the same volume, is characterized by an average particle size of 100-800 nm, and when diluted 100 times, 5-80 nm (determined by dynamic light scattering using the Malvern Zetasizer Nano ZS analyzer).
  • rifapentin 100 mg was dissolved in 2.5 ml of isopropanol and added to 100 ml of a 5% aqueous solution of human serum albumin. Stirred on a magnetic stirrer until the organic solvent is completely removed, at a stirring speed of 300-400 rpm, or the organic solvent is removed by distillation under reduced pressure (using a rotary evaporator); filtered through a glass filter (pore 1), cryoprotectant (5% mannitol) is added, frozen (at a temperature of -60-70 ° C) and lyophilized (or dried by spray drying).
  • Rp rifapentin
  • the resulting lyophilizate powder when resuspended in the same volume, is characterized by an average particle size of 100-800 nm, and when diluted 100 times, 5-80 nm (determined by dynamic light scattering using the Malvern Zetasizer Nano ZS analyzer).
  • rifaximin 13o mg was dissolved in 2.0 ml of ethanol and added to 100 ml of a 4% aqueous solution of human serum albumin. Stirred on a magnetic stirrer until the organic solvent is completely removed, at a stirring speed of 300-400 rpm, or the organic solvent is removed by distillation under reduced pressure (using a rotary evaporator); filtered through a glass filter (pore 1), cryoprotectant (3% mannitol) is added, frozen (at a temperature of -60-70 ° C) and lyophilized (or dried by spray drying).
  • Received lyophilisate powder when resuspended in the same volume is characterized by an average particle size of 100-800 nm, and when diluted 100 times - 5-80 nm (determined by dynamic light scattering using a Malvern Zetasizer Nano ZS analyzer).
  • mice linear Balb / c mice, females, age 7-8 weeks, weight 20-22 g. There are 10 animals in each experimental group.
  • Infection intravenous administration in the lateral tail vein, dose - 5x10 6 CFU of Mycobacterium tuberculosis strain H37Rv. Used stock stock of strain Mycobacterium tuberculosis H37Rv, which is stored at -70 ° C.
  • Antibiotics rifabutin (substance) and the intravenous form according to isorethenium (rifabutin iv - 687), were prepared no more than an hour before the start of therapy in accordance with passport recommendations. To prepare a rifabutin solution, 10 mg of the substance was ground in a mortar, 4 ml of sterile distilled water was added and dissolved by prolonged pipetting to a final concentration of 2.5 mg / ml. The intravenous form (rifabutin iv 687) was diluted with water to a final concentration of 2.5 mg / ml.
  • the duration of therapy was 4 weeks. Treatment began on day 7 after infection.
  • the drugs were administered to animals of the experimental groups for 4 weeks 3 times a week (Monday, Wednesday, Friday) iv in a volume of 0.2 ml into the lateral tail vein in the following doses: 500, 100 and 20 ⁇ g / mouse. Mice in the control group were injected with 0.2 ml of physiological saline.
  • FIG. 5 illustrating the dependence of the effectiveness of tuberculosis treatment on the form, dose and method of administration of the rifabutin antibiotic, where Lg 10 CFU of M. tuberculosis is shown on the ordinate axis when sowing from the organs of mice, the doses used for treatment are shown on the abscissa axis, the data are also shown in Tables 2 and 2a.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte au domaine de la médecine, de la pharmacie, des nanotechnologies et de la chimie des colloïdes, et concerne notamment un procédé de préparation d'une forme médicamenteuse soluble dans l'eau (composition pharmaceutique) d'un antibiotique issu du groupe des rifamycines comme la rifabutine, la rifampicine, la rifapentine, la rifaximine ou leurs dérivés pharmaceutiquement acceptables afin de traiter la tuberculose. Le but de la présente invention est de simplifier les techniques de production de la composition pharmaceutique d'antibiotique groupe des rifamycines, ainsi que d'exclure les solvants chloro-organique hautement toxiques. L'invention a pour but de produire une composition pharmaceutique d'antibiotique du groupe des rifamycines pouvant être administrées par voie parentérale (interne) chez un patient. Cette composition est obtenue par un procédé consistant à : dissoudre un antibiotique du groupe des rifamycines dans un solvant organique choisi dans le groupe des solvants se mélangeant à l'eau; b) ajouter à la solution obtenue lors de l'étape a) une solution aqueuse d'albumine obtenue en dissolvant 1-10% m/о d'albumine dans de l'eau déminéralisée stérilisée; c) agiter le mélange obtenu; d) filtrer; e) ajouter un cryo-protecteur; f) congeler le tout; g) et sécher le produit (lyophilisation ou pulvérisation).
PCT/EA2011/000014 2010-12-27 2011-12-21 Procédé de préparation d'une forme médicamenteuse soluble dans l'eau d'antibiotique issu du groupe des rifamycines et composition obtenue par ce procédé Ceased WO2012089220A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AP2013007013A AP2013007013A0 (en) 2010-12-27 2011-12-21 Method for producing a watersoluble medicinal formof an antibiotic from the group consisting of rif amycins, and composition produced by said method
UAA201309032A UA108527C2 (uk) 2010-12-27 2011-12-21 Спосіб одержання водорозчинної лікарської форми антибіотика з групи рифаміцинів
ZA2013/05684A ZA201305684B (en) 2010-12-27 2013-07-26 Method for producing a water-soluble medicinal form of an antibiotic from the group consisting of rifamycins,and composition produced by said method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201001854 2010-12-27
EA201001854A EA021117B1 (ru) 2010-12-27 2010-12-27 Способ получения водорастворимой фармацевтической композиции антибиотика из группы рифамицинов и фармацевтическая композиция для лечения туберкулеза и заболеваний, связанных с helicobacter pylori

Publications (1)

Publication Number Publication Date
WO2012089220A1 true WO2012089220A1 (fr) 2012-07-05

Family

ID=46382331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EA2011/000014 Ceased WO2012089220A1 (fr) 2010-12-27 2011-12-21 Procédé de préparation d'une forme médicamenteuse soluble dans l'eau d'antibiotique issu du groupe des rifamycines et composition obtenue par ce procédé

Country Status (5)

Country Link
AP (1) AP2013007013A0 (fr)
EA (1) EA021117B1 (fr)
UA (1) UA108527C2 (fr)
WO (1) WO2012089220A1 (fr)
ZA (1) ZA201305684B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105012249A (zh) * 2014-04-30 2015-11-04 北京星昊医药股份有限公司 一种注射用利福平及其制备方法
WO2015104668A3 (fr) * 2014-01-09 2015-11-12 Camus Pharma Pvt. Ltd. Formulations lyophilisées à usage parentéral

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2540510C2 (ru) * 2013-06-10 2015-02-10 Общество с ограниченной ответственностью "Научно-Производственный Комплекс "Наноситема" Способ получения биосовместимых галлий(iii)-содержащих высокодисперсных частиц для изготовления диагностических препаратов для позитронно-эмиссионной томографии

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1875941A (zh) * 2006-06-29 2006-12-13 西北农林科技大学 一种利福平纳米乳剂抗生素药物及其制备方法
RU2337711C1 (ru) * 2007-04-04 2008-11-10 Общество С Ограниченной Ответственностью "Научно-Производственный Комплекс "Наносистема" Средство для лечения бактериальных инфекций
EA200900215A1 (ru) * 2009-02-24 2010-04-30 Ооо «Научно-Производственный Комплекс "Наносистема"» Фармацевтическая композиция для лечения туберкулеза и заболеваний, опосредованных helicobacter pilori, на основе твердых липидных наночастиц, и способ лечения туберкулеза
EA200900214A1 (ru) * 2009-02-24 2010-04-30 Ооо «Научно-Производственный Комплекс "Наносистема"» Фармацевтическая композиция рифабутина для лечения туберкулеза, способ ее получения и способ лечения

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200801388A1 (ru) * 2008-06-20 2009-08-28 Ооо «Нпк "Наносистема"» Фармацевтическая композиция для лечения туберкулеза и заболеваний, опосредованных helicobacter pilory, на основе полимерных наночастиц, способ ее получения и способ лечения

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1875941A (zh) * 2006-06-29 2006-12-13 西北农林科技大学 一种利福平纳米乳剂抗生素药物及其制备方法
RU2337711C1 (ru) * 2007-04-04 2008-11-10 Общество С Ограниченной Ответственностью "Научно-Производственный Комплекс "Наносистема" Средство для лечения бактериальных инфекций
EA200900215A1 (ru) * 2009-02-24 2010-04-30 Ооо «Научно-Производственный Комплекс "Наносистема"» Фармацевтическая композиция для лечения туберкулеза и заболеваний, опосредованных helicobacter pilori, на основе твердых липидных наночастиц, и способ лечения туберкулеза
EA200900214A1 (ru) * 2009-02-24 2010-04-30 Ооо «Научно-Производственный Комплекс "Наносистема"» Фармацевтическая композиция рифабутина для лечения туберкулеза, способ ее получения и способ лечения

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104668A3 (fr) * 2014-01-09 2015-11-12 Camus Pharma Pvt. Ltd. Formulations lyophilisées à usage parentéral
CN105012249A (zh) * 2014-04-30 2015-11-04 北京星昊医药股份有限公司 一种注射用利福平及其制备方法

Also Published As

Publication number Publication date
UA108527C2 (uk) 2015-05-12
AP2013007013A0 (en) 2013-07-31
ZA201305684B (en) 2014-10-29
EA021117B1 (ru) 2015-04-30
EA201001854A1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
Shegokar et al. Present status of nanoparticle research for treatment of tuberculosis
JP5898627B2 (ja) エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
US9351933B2 (en) Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
RU2705998C2 (ru) Применение полимерных эксципиентов для лиофилизации или заморозки частиц
Dube et al. Tuberculosis: from molecular pathogenesis to effective drug carrier design
NZ571354A (en) Polylactide nanoparticles
JP5449388B2 (ja) 耐性がん治療用高分子ミセル組成物及びその製造方法
EP2512487A2 (fr) Nanoparticules polymères thérapeutiques comprenant de corticostéroïdes, et procédés pour les fabriquer et les utiliser
JP5780775B2 (ja) プロスタグランジンｉ２誘導体を含有するナノ粒子
KR20170023173A (ko) 표적화된 치료 나노입자 및 그의 제조 및 사용 방법
CN101820919A (zh) 用于局部药物输送的可注射聚合物-脂质共混物
JP5425890B2 (ja) 難溶性薬物を含む均一なサイズの高分子ナノ粒子製造方法
WO2012089220A1 (fr) Procédé de préparation d'une forme médicamenteuse soluble dans l'eau d'antibiotique issu du groupe des rifamycines et composition obtenue par ce procédé
RU2337711C1 (ru) Средство для лечения бактериальных инфекций
EA013569B1 (ru) Фармацевтическая композиция рифабутина для лечения туберкулеза и заболеваний, опосредованных helicobacter pylori, способ ее получения и способ лечения
JP2010531827A (ja) 抗腫瘍剤用ビヒクルとしてのシクロデキストリン系ナノスポンジ
Patil et al. Nanocarrier-based methods for effective antitubercular drug delivery.
RU2308970C1 (ru) Антибактериальное средство для лечения внутриклеточных инфекций
Kumar et al. Nanotechnology: A focus on treatment of tuberculosis
EA016410B1 (ru) Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
CN114901363A (zh) 长效治疗剂组合物及其方法
RU2418585C1 (ru) Лекарственное средство пролонгированного действия для лечения резистентных форм туберкулеза на основе рифампицина
WO2017046037A1 (fr) Nanoparticules chargées de principes actifs, leur procédé de préparation et leurs utilisations
US20170071866A1 (en) Nanoparticles loaded with active ingredients, their process of preparation, and their uses
Sun Nanoparticle depot for intraperitoneal chemotherapy of ovarian cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11853562

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11853562

Country of ref document: EP

Kind code of ref document: A1